Home
>
US Stocks
>
Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. (INO)

$0.572

-0.03

(-4.44%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Inovio Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 124.66K → 114.94K (in $), with an average decrease of 7.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -54.46M → -40.64M (in $), with an average increase of 34.0% per quarter

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 111.9%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 119.1%

Performance

  • $0.57
    $0.60
    $0.57
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.98%

    Upside

    4.98%

    downward going graph
  • $0.56
    $2.82
    $0.57
    downward going graph

    2.11%

    Downside

    52 Weeks Volatility :80.21%

    Upside

    79.79%

    downward going graph

Returns

PeriodInovio Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-51.73%
0.7%
-6.8%
6 Months
-68.82%
-8.3%
-6.0%
1 Year
-65.99%
-1.9%
-4.6%
3 Years
-95.97%
25.3%
25.9%

Highlights

Market Capitalization
155.0M
Book Value
$0.76
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.97
PEG Ratio
0.0
Wall Street Target Price
1.33
Profit Margin
0.0%
Operating Margin TTM
-2355.96%
Return On Assets TTM
-42.09%
Return On Equity TTM
-87.1%
Revenue TTM
10.2M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
-42.3%
Gross Profit TTM
-177.4M
EBITDA
-235.9M
Diluted Eps TTM
-0.97
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.56
EPS Estimate Next Year
-0.38
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 12 Wall street analysts offering stock ratings for Inovio Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
6
6
6
Sell
6
6
6

Analyst Forecast

What analysts predicted

Upside of 132.52%

Current $0.57
Target $1.33

Company Financials

FY17Y/Y Change
Revenue
42.2M
↑ 19.37%
Net Income
-88.2M
↑ 19.62%
Net Profit Margin
-208.92%
↓ 0.43%
FY18Y/Y Change
Revenue
30.5M
↓ 27.8%
Net Income
-97.0M
↑ 9.93%
Net Profit Margin
-318.12%
↓ 109.2%
FY19Y/Y Change
Revenue
4.1M
↓ 86.51%
Net Income
-119.4M
↑ 23.09%
Net Profit Margin
-2.9K%
↓ 2584.63%
FY20Y/Y Change
Revenue
7.4M
↑ 80.24%
Net Income
-166.4M
↑ 39.42%
Net Profit Margin
-2.2K%
↑ 657.36%
FY21Y/Y Change
Revenue
1.8M
↓ 76.05%
Net Income
-303.7M
↑ 82.47%
Net Profit Margin
-17.1K%
↓ 14864.48%
FY22Y/Y Change
Revenue
10.3M
↑ 478.23%
Net Income
-279.8M
↓ 7.85%
Net Profit Margin
-2.7K%
↑ 14383.2%
Q4 FY21Q/Q Change
Revenue
839.1K
↑ 187.67%
Net Income
-106.9M
↑ 77.75%
Net Profit Margin
-12.7K%
↑ 7881.89%
Q1 FY22Q/Q Change
Revenue
199.1K
↓ 76.28%
Net Income
-79.1M
↓ 26.06%
Net Profit Margin
-39.7K%
↓ 26975.49%
Q2 FY22Q/Q Change
Revenue
784.4K
↑ 294.02%
Net Income
-108.5M
↑ 37.21%
Net Profit Margin
-13.8K%
↑ 25888.8%
Q3 FY22Q/Q Change
Revenue
9.2K
↓ 98.83%
Net Income
-37.8K
↓ 99.97%
Net Profit Margin
-412.75%
↑ 13419.22%
Q4 FY22Q/Q Change
Revenue
124.7K
↑ 1261.86%
Net Income
-54.5M
↑ 144043.77%
Net Profit Margin
-43.7K%
↓ 43274.49%
Q1 FY23Q/Q Change
Revenue
114.9K
↓ 7.8%
Net Income
-40.6M
↓ 25.36%
Net Profit Margin
-35.4K%
↑ 8322.48%
FY17Y/Y Change
Total Assets
187.2M
↑ 7.79%
Total Liabilities
44.8M
↓ 11.08%
FY18Y/Y Change
Total Assets
131.1M
↓ 29.98%
Total Liabilities
44.1M
↓ 1.5%
FY19Y/Y Change
Total Assets
144.0M
↑ 9.79%
Total Liabilities
138.5M
↑ 214.3%
FY20Y/Y Change
Total Assets
539.8M
↑ 274.97%
Total Liabilities
78.6M
↓ 43.25%
FY21Y/Y Change
Total Assets
495.9M
↓ 8.12%
Total Liabilities
96.3M
↑ 22.43%
FY22Y/Y Change
Total Assets
348.5M
↓ 29.72%
Total Liabilities
126.2M
↑ 31.06%
Q4 FY21Q/Q Change
Total Assets
495.9M
↓ 7.43%
Total Liabilities
96.3M
↑ 17.13%
Q1 FY22Q/Q Change
Total Assets
445.5M
↓ 10.17%
Total Liabilities
90.4M
↓ 6.07%
Q2 FY22Q/Q Change
Total Assets
459.4M
↑ 3.12%
Total Liabilities
161.7M
↑ 78.85%
Q3 FY22Q/Q Change
Total Assets
392.0M
↓ 14.68%
Total Liabilities
125.3M
↓ 22.54%
Q4 FY22Q/Q Change
Total Assets
348.5M
↓ 11.08%
Total Liabilities
126.2M
↑ 0.72%
Q1 FY23Q/Q Change
Total Assets
266.6M
↓ 23.51%
Total Liabilities
67.4M
↓ 46.6%
FY17Y/Y Change
Operating Cash Flow
-63.2M
↑ 1.05%
Investing Cash Flow
-27.8M
↓ 271.04%
Financing Cash Flow
95.7M
↑ 1128.85%
FY18Y/Y Change
Operating Cash Flow
-73.6M
↑ 16.36%
Investing Cash Flow
42.4M
↓ 252.42%
Financing Cash Flow
31.0M
↓ 67.56%
FY19Y/Y Change
Operating Cash Flow
-97.9M
↑ 33.04%
Investing Cash Flow
-9.0M
↓ 121.32%
Financing Cash Flow
105.4M
↑ 239.58%
FY20Y/Y Change
Operating Cash Flow
-178.0M
↑ 81.89%
Investing Cash Flow
-58.8M
↑ 550.04%
Financing Cash Flow
465.3M
↑ 341.45%
FY21Y/Y Change
Operating Cash Flow
-215.7M
↑ 21.2%
Investing Cash Flow
-175.3M
↑ 198.23%
Financing Cash Flow
211.5M
↓ 54.54%
FY22Y/Y Change
Operating Cash Flow
-216.2M
↑ 0.23%
Investing Cash Flow
109.6M
↓ 162.5%
Financing Cash Flow
81.8M
↓ 61.3%
Q4 FY21Q/Q Change
Operating Cash Flow
-37.9M
↓ 18.5%
Investing Cash Flow
-6.5M
↓ 111.61%
Financing Cash Flow
47.6M
↓ 10897.89%
Q1 FY22Q/Q Change
Operating Cash Flow
-61.9M
↑ 63.32%
Investing Cash Flow
21.3M
↓ 428.49%
Financing Cash Flow
28.4M
↓ 40.28%
Q2 FY22Q/Q Change
Operating Cash Flow
-50.5M
↓ 18.35%
Investing Cash Flow
-10.3M
↓ 148.3%
Financing Cash Flow
42.9M
↑ 51.08%
Q3 FY22Q/Q Change
Operating Cash Flow
-118.0M
↑ 133.52%
Investing Cash Flow
44.6M
↓ 532.42%
Financing Cash Flow
46.8M
↑ 8.88%
Q4 FY22Q/Q Change
Operating Cash Flow
-36.3M
↓ 69.2%
Investing Cash Flow
54.0M
↑ 21.2%
Financing Cash Flow
6.7M
↓ 85.74%
Q1 FY23Q/Q Change
Operating Cash Flow
-36.7M
↑ 0.89%
Investing Cash Flow
19.0M
↓ 64.82%
Financing Cash Flow
-424.7K
↓ 106.37%

Technicals Summary

Sell

Neutral

Buy

Inovio Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
-21.41%
-68.82%
-65.99%
-95.97%
-87.13%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
NA
NA
0.0
-0.56
-0.87
-0.42
0.0
0.76
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Sell
$155.0M
-87.13%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • State Street Corporation

    10.62%

  • BlackRock Inc

    8.86%

  • Vanguard Group Inc

    6.95%

  • D. E. Shaw & Co LP

    2.52%

  • Geode Capital Management, LLC

    1.86%

  • Millennium Management LLC

    1.64%

Corporate Announcements

  • Inovio Pharmaceuticals, Inc. Earnings

    Inovio Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. INOVIO's lead immunotherapy candidate, VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, cleared high-risk HPV-16 and/or HPV-18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as infectious disease DNA vaccine development programs in coronaviruses associated with COVID-19 diseases and MERS, Lassa fever, Ebola, and HIV. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards 'W' designation recognizing companies with more than 20% women on their board of directors.

Organization
Inovio Pharmaceuticals, Inc.
Employees
184
CEO
Dr. Jacqueline E. Shea Ph.D.
Industry
Health Technology

Discover More

FAQs